Insight

Catherine Alix-Panabières Will Present Her Latest Research on Circulating Tumor Cells in Immuno-Oncology at ISMRC 2025

Catherine Alix-Panabières/umontpellier.fr

May 4, 2025, 09:56

Catherine Alix-Panabières Will Present Her Latest Research on Circulating Tumor Cells in Immuno-Oncology at ISMRC 2025

Catherine Alix-Panabières, Full Professor of Oncology at the Faculty of Medicine of the University of Montpellier, shared a post by International Symposium on Minimal Residual Cancer on LinkedIn, adding:

“Welcome to beautiful Nice on the stunning French Riviera! We’re thrilled to welcome you to what promises to be an inspiring event!

The program is exceptional, and we look forward to sparking new and fruitful collaborations between participants from academia, diagnostics, and the pharmaceutical industry.

Haven’t registered yet? There’s still time!

See you in just a few days – we can’t wait!”

Quoting International Symposium on Minimal Residual Cancer‘s post:

“Prof. Catherine Alix-Panabières, Director of the LCCRH in Montpellier and co-creator of the term “liquid biopsy,” will present her latest research on circulating tumor cells in immuno-oncology at ISMRC 2025.

Her talk, “Liquid biopsy: pioneering the future of immuno-oncology with CTCs,” will be featured in the ARC Foundation Session.

Register now. The ISMRC 2025 is organized by Paul Hofman from IHU RespirERA, Catherine Alix-Panabières and Klaus Pantel.”

Catherine Alix-Panabières

Catherine Alix-Panabières welcomed participants to the International Symposium on Minimal Residual Cancer (ISMRC) 2025, taking place in Nice on the French Riviera. She expressed enthusiasm about the upcoming event, highlighting its exceptional program and the opportunity it offers for collaboration across academia, diagnostics, and the pharmaceutical industry.

At the symposium, Alix-Panabières will present her latest research on circulating tumor cells in immuno-oncology during the ARC Foundation Session. Her talk, titled “Liquid biopsy: pioneering the future of immuno-oncology with CTCs,” reflects her leadership in the field and ongoing contributions to cancer research.